You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

MMR deficient

Showing 1 - 25 of 996
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Colon Cancer Trial (Pembrolizumab)

Not yet recruiting
  • Colon Cancer
  • (no location specified)
Dec 14, 2022

Adenocarcinoma of the Colon Trial in London (Pembrolizumab)

Recruiting
  • Adenocarcinoma of the Colon
  • London, United Kingdom
    University College Hospital
Jul 20, 2022

Colorectal Cancer Trial in Essen (Atezolizumab)

Recruiting
  • Colorectal Cancer
  • Essen, Germany
    Westdeutsches Tumorzentrum
Feb 14, 2022

Endometrial Cancer Trial in France (Carboplatin-Paclitaxel, Dostarlimab)

Recruiting
  • Endometrial Cancer
  • Angers, France
  • +40 more
Aug 9, 2022

Colorectal Cancer Not MSI-H or MMR-deficient, GIST, Oesophageal or Gastric Carcinoma Trial in France (Phase 1 : Regorafenib,

Recruiting
  • Colorectal Cancer Not MSI-H or MMR-deficient
  • +9 more
  • Phase 1 : Regorafenib
  • +4 more
  • Bordeaux, France
  • +6 more
Dec 6, 2021

Endometrial Cancer Trial in United States (Intensity modulated radiation therapy (IMRT), Dostarlimab)

Recruiting
  • Endometrial Cancer
  • Basking Ridge, New Jersey
  • +6 more
Jul 5, 2022

Colorectal Cancer (CRC), Endometrial Cancer, Melanoma Trial in United States (Pembrolizumab, itacitinib, INCB050465)

Completed
  • Colorectal Cancer (CRC)
  • +10 more
  • San Francisco, California
  • +16 more
Mar 30, 2022

Metastatic Cancer Colorectal Trial in France (Ipilimumab 200 MG in 40 ML Injection, Nivolumab 10 MG/ML)

Active, not recruiting
  • Metastatic Cancer Colorectal
  • Ipilimumab 200 MG in 40 ML Injection
  • Nivolumab 10 MG/ML
  • Avignon, France
  • +7 more
Jan 26, 2021

Colorectal Tumors, Microsatellite Instability Trial in Milano, Rozzano (temozolomide (induction),, pembrolizumab (treatment))

Recruiting
  • Colorectal Neoplasms
  • Microsatellite Instability
  • temozolomide (induction),
  • pembrolizumab (treatment)
  • Milano, Italy
  • +3 more
Sep 28, 2022

Recurrent Endometrial Adenocarcinoma, Recurrent Endometrial Carcinoma, Recurrent Endometrial Clear Cell Adenocarcinoma Trial in

Recruiting
  • Recurrent Endometrial Adenocarcinoma
  • +8 more
  • Ipilimumab
  • Nivolumab
  • Iowa City, Iowa
  • +9 more
Jan 27, 2023

Immunotherapy in Advanced or Locally Advanced dMMR/MSI-H

Recruiting
  • Colorectal Cancer
    • Shanghai, China
      Fudan University Shanghai Cancer Center
    Oct 18, 2023

    Endometrial Adenocarcinoma Trial in Helsinki (Comparison of adjuvant therapies)

    Recruiting
    • Endometrial Adenocarcinoma
    • Comparison of adjuvant therapies
    • Helsinki, Finland
      Helsinki University Hospital
    Dec 8, 2022

    Refractory MSI - H Solid Tumors Prior of PD-(L) 1 Therapy, MSI-H Tumors Trial in Baltimore (Nivolumab, Relatlimab)

    Recruiting
    • Refractory MSI - H Solid Tumors Prior of PD-(L) 1 Therapy
    • MSI-H Tumors
    • Baltimore, Maryland
      Sidney Kimmel Comprehensive Cancer Center
    Mar 14, 2022

    Endometrial Cancer Trial in Paris (cervical cytology during surgery.)

    Not yet recruiting
    • Endometrial Cancer
    • cervical cytology during surgery.
    • Paris, France
      Medical genetics department
    Feb 22, 2023

    Rectal Tumors Trial in Cleveland (Pembrolizumab, External beam radiation, Capecitabine)

    Recruiting
    • Rectal Neoplasms
    • Cleveland, Ohio
      Cleveland Clinic, Case Comprehensive Cancer Center
    Jan 25, 2023

    Endometrial Adenocarcinoma, Endometrial Carcinoma, Lynch Syndrome Trial in United States (Genetic Counseling, Genetic Testing,

    Active, not recruiting
    • Endometrial Adenocarcinoma
    • +3 more
    • Genetic Counseling
    • +3 more
    • Akron, Ohio
    • +8 more
    Dec 2, 2022

    Rectal Tumors Trial (procedure, drug, diagnostic test)

    Not yet recruiting
    • Rectal Neoplasms
    • Arterial chemoembolization
    • +4 more
    • (no location specified)
    Jun 26, 2022

    Solid Tumor Trial in Beijing (KN035)

    Recruiting
    • Solid Tumor
    • KN035
    • Beijing, Beijing, China
      Peking University Cancer Hospital, Peking University
    Apr 5, 2022

    Colon Cancer Trial (Tislelizumab)

    Not yet recruiting
    • Colon Cancer
    • (no location specified)
    Feb 7, 2022

    Advanced Solid Tumors Trial in London, Southampton (TT-702)

    Recruiting
    • Advanced Solid Tumors
    • London, United Kingdom
    • +1 more
    Feb 28, 2022

    MSI-H, PD-1 Immunotherapy, Gastric Cancer Trial in Shanghai (SOX, XELOX, Observation)

    Not yet recruiting
    • MSI-H
    • +3 more
    • Shanghai, China
      Dazhi Xu
    Jul 20, 2022

    Merkel Cell Carcinoma Trial in Milan (Retifanlimab, Cisplatin, Etoposide)

    Recruiting
    • Merkel Cell Carcinoma
    • Milan, Italy
      Fondazione IRCCS Istituto Nazionale dei Tumori di Milano
    Jan 4, 2023

    Colorectal Cancer, Mismatch Repair-deficient (dMMR), Microsatellite Instability-high (MSI-H) Trial in ZhengZhou (Cadonilimab

    Not yet recruiting
    • Colorectal Cancer
    • +3 more
    • Cadonilimab (®), a PD-1/CTLA-4 bi-specific antibody
    • ZhengZhou, Henan, China
      Henan Cancer Hospital/The affiliated Cancer Hospital of ZhengZho
    Jun 18, 2023

    Metastatic Colorectal Cancer Trial in Seoul (Avelumab)

    Unknown status
    • Metastatic Colorectal Cancer
    • Seoul, Songpa, Korea, Republic of
      Asan Medical Center
    Apr 1, 2020

    MSI-H Colorectal Cancer Trial (colorectal resection)

    Completed
    • MSI-H Colorectal Cancer
    • colorectal resection
    • (no location specified)
    May 22, 2023